The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Long-term survival in primary CNS lymphoma.
Abstract
PURPOSE: We have previously reported on 31 patients with primary CNS lymphoma (PCNSL) treated between 1986 and 1992 with methotrexate (MTX), cranial radiotherapy (RT), and high-dose cytarabine who remained free of disease longer than historical controls. PATIENTS AND METHODS: We performed a follow-up analysis of our original cohort and now report their long-term survival and late treatment-related toxicity. RESULTS: The median cause-specific survival was 42 months, with a five-year survival of 22.3% compared with 3% to 4% in historical controls treated with RT alone. Age less than 50 years at diagnosis was a significant prognostic factor for survival (P = .01). Median disease-free survival was 40.3 months; 15 patients relapsed, all but one in the CNS. Late treatment-related toxicity was observed in nearly one third of patients and those more than 60 years of age were at substantially higher risk (P < .0001). CONCLUSION: Combined modality therapy for PCNSL has improved survival, but relapse is common and late neurologic toxicity is a significant complication. Although this approach is highly effective for younger patients, efficacious but less neurotoxic regimens need to be developed for older patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiation‐induced dementia in patients cured of brain metastases
DeAngelis, L. M., Delattre, J.-Y., & Posner, J. B. (1989) · Neurology · doi:10.1212/wnl.39.6.789 · Cited by 941
Self-citationPrimary central nervous system lymphoma
Hochberg, F. H., & Miller, D. C. (1988) · Journal of neurosurgery · doi:10.3171/jns.1988.68.6.0835 · Cited by 821
Crossen, J. R., Garwood, D., Glatstein, E., & Neuwelt, E. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.627 · Cited by 721
Nelson, D. F., Martz, K. L., Bonner, H., Nelson, J. S., Newall, J., Kerman, H. D., Thomson, J. W., & Murray, K. J. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90538-s · Cited by 635
Combined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 544
Self-citationNeurologic sequelae of methotrexate and ionizing radiation: a new classification.
Bleyer, W. A. (1981) · PubMed · Cited by 265
Sa, D., Henner, W. D., Crossen, J. R., Cm, T., Petrillo, A., Braziel, R. M., & Neuwelt, E. A. (1996) · PubMed · Cited by 125
Cited by
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
Treatment for Primary CNS Lymphoma: The Next Step
Abrey, L. E., Yahalom, J., & DeAngelis, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3144 · Cited by 607
Self-citationHouillier, C., Taillandier, L., Dureau, S., Lamy, T., Laadhari, M., Chinot, O., Moluçon-Chabrot, C., Soubeyran, P., Gressin, R., Choquet, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00306 · Cited by 287
Metadata
- Authors
- Abrey, L. E., DeAngelis, L. M., & Yahalom, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-03
- Volume
- 16
- Issue
- 3
- Pages
- 859-863
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2159708587
- Cited by
- 577
- References
- 7
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term survival in primary CNS lymphoma. https://app.cochat.ai/papers/10.1200/jco.1998.16.3.859
- The paper
- Abrey, L. E., DeAngelis, L. M., & Yahalom, J. (1998). Long-term survival in primary CNS lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.3.859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
